Home>
US Stocks>
Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc share price today

(AMPH)

Amphastar Pharmaceuticals Inc share price is $43.8 & ₹3,707.36 as on 7 Dec 2024, 2.30 'hrs' IST

$43.8

▲

0.2

(0.46%)

Market is closed - opens 8 PM, 09 Dec 2024

View live Amphastar Pharmaceuticals Inc share price in Dollar and Rupees. Guide to invest in Amphastar Pharmaceuticals Inc from India. Also see the sentimental analysis on Indian investors investing in Amphastar Pharmaceuticals Inc. Get details on the Indian mutual funds that are investing in Amphastar Pharmaceuticals Inc. Get Analyst recommendations and forecasts along with all the Amphastar Pharmaceuticals Inc's financials.

Amphastar Pharmaceuticals Inc share price movements

$43.47
$44.27
$43.80
0.75%
Downside
Day's Volatility :1.81%
Upside
1.06%
$36.56
$65.92
$43.80
16.53%
Downside
52 Weeks Volatility :44.54%
Upside
33.56%

Amphastar Pharmaceuticals Inc Returns

Period	Amphastar Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-2.11%	-5.7%	0.0%
6 Months	4.71%	-0.9%	0.0%
1 Year	-23.2%	10.0%	0.0%
3 Years	104.89%	9.3%	-21.5%

Amphastar Pharmaceuticals Inc Key Statistics

in dollars & INR

Previous Close	$43.6
Open	$43.79
Today's High	$44.27
Today's Low	$43.47
Market Capitalization	$2.1B
Today's Volume	$690.7K
52 Week High	$65.9249
52 Week Low	$36.56
Revenue TTM	$723.5M
EBITDA	$266.6M
Earnings Per Share (EPS)	$2.97
PE Ratio	14.92
Profit Margin	21.8%
Quarterly Earnings Growth YOY	-0.14%
Return On Equity TTM	23.85%

How to invest in Amphastar Pharmaceuticals Inc from India?

It is very easy for Indian residents to invest directly in Amphastar Pharmaceuticals Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Amphastar Pharmaceuticals Inc stock in both rupees (INR) and dollars (USD). Search for Amphastar Pharmaceuticals Inc or AMPH on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Amphastar Pharmaceuticals Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Amphastar Pharmaceuticals Inc shares which would translate to 0.019 fractional shares of Amphastar Pharmaceuticals Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Amphastar Pharmaceuticals Inc

30%

Period: Sep 7, 2024 to Dec 6, 2024. Change in 30 Days versus previous period

Search volume for Amphastar Pharmaceuticals Inc on INDmoney from India has grown in the last 30 days as on Dec 7, 2024. 30% more investors are searching Amphastar Pharmaceuticals Inc in the last 30 days versus the previous period.

Global Institutional Holdings in Amphastar Pharmaceuticals Inc

BlackRock Inc
12.36%
Vanguard Group Inc
5.64%
TD Asset Management Inc
4.44%
Federated Hermes Inc
4.05%
Neuberger Berman Group LLC
3.36%
State Street Corp
3.18%

Analyst Recommendation on Amphastar Pharmaceuticals Inc

Buy

75%Buy

25%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Amphastar Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Amphastar Pharmaceuticals Inc

What analysts predicted

Upside of 32.88%

Current:

$43.80

Target:

$58.20

Insights on Amphastar Pharmaceuticals Inc

Increasing Revenue
Revenue is up for the last 3 quarters, 171.83M → 188.81M (in $), with an average increase of 4.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 37.94M → 40.42M (in $), with an average increase of 6.1% per quarter
Vs CTLT
In the last 1 year, Catalent, Inc. has given 65.9% return, outperforming this stock by 89.5%

Amphastar Pharmaceuticals Inc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$294.7M	↑ 22.69%
Net Income	$-5.7M	↓ 227.28%
Net Profit Margin	-1.95%	↓ 3.83%

	FY19	Y/Y Change
Revenue	$322.4M	↑ 9.4%
Net Income	$48.9M	↓ 952.89%
Net Profit Margin	15.18%	↑ 17.13%

	FY20	Y/Y Change
Revenue	$349.8M	↑ 8.53%
Net Income	$1.1M	↓ 97.76%
Net Profit Margin	0.31%	↓ 14.87%

	FY21	Y/Y Change
Revenue	$437.8M	↑ 25.13%
Net Income	$62.1M	↑ 5562.35%
Net Profit Margin	14.19%	↑ 13.88%

	FY22	Y/Y Change
Revenue	$499.0M	↑ 13.98%
Net Income	$91.4M	↑ 47.12%
Net Profit Margin	18.31%	↑ 4.12%

	FY23	Y/Y Change
Revenue	$644.4M	↑ 29.14%
Net Income	$137.5M	↑ 50.51%
Net Profit Margin	21.34%	↑ 3.03%

	Q2 FY23	Q/Q Change
Revenue	$145.7M	↑ 4.06%
Net Income	$26.1M	↑ 0.35%
Net Profit Margin	17.93%	↓ 0.66%

	Q3 FY23	Q/Q Change
Revenue	$180.6M	↑ 23.91%
Net Income	$49.2M	↑ 88.42%
Net Profit Margin	27.26%	↑ 9.33%

	Q4 FY23	Q/Q Change
Revenue	$178.1M	↓ 1.36%
Net Income	$36.2M	↓ 26.52%
Net Profit Margin	20.31%	↓ 6.95%

	Q1 FY24	Q/Q Change
Revenue	$171.8M	↓ 3.52%
Net Income	$43.2M	↑ 19.38%
Net Profit Margin	25.13%	↑ 4.82%

	Q2 FY24	Q/Q Change
Revenue	$182.4M	↑ 6.14%
Net Income	$37.9M	↓ 12.11%
Net Profit Margin	20.81%	↓ 4.32%

	Q3 FY24	Q/Q Change
Revenue	$188.8M	↑ 3.52%
Net Income	$40.4M	↑ 6.54%
Net Profit Margin	21.41%	↑ 0.6%

	FY18	Y/Y Change
Total Assets	$513.6M	↑ 12.95%
Total Liabilities	$149.2M	↑ 27.16%

	FY19	Y/Y Change
Total Assets	$587.0M	↑ 14.29%
Total Liabilities	$159.4M	↑ 6.86%

	FY20	Y/Y Change
Total Assets	$631.2M	↑ 7.54%
Total Liabilities	$182.5M	↑ 14.47%

	FY21	Y/Y Change
Total Assets	$671.5M	↑ 6.38%
Total Liabilities	$226.0M	↑ 23.83%

	FY22	Y/Y Change
Total Assets	$742.0M	↑ 10.49%
Total Liabilities	$213.3M	↓ 5.61%

	FY23	Y/Y Change
Total Assets	$1.5B	↑ 103.9%
Total Liabilities	$873.5M	↑ 309.46%

	Q2 FY23	Q/Q Change
Total Assets	$1.4B	↑ 78.15%
Total Liabilities	$789.0M	↑ 250.56%

	Q3 FY23	Q/Q Change
Total Assets	$1.5B	↑ 12.07%
Total Liabilities	$949.5M	↑ 20.34%

	Q4 FY23	Q/Q Change
Total Assets	$1.5B	↓ 2.05%
Total Liabilities	$873.5M	↓ 8.0%

	Q1 FY24	Q/Q Change
Total Assets	$1.6B	↑ 4.06%
Total Liabilities	$902.0M	↑ 3.26%

	Q2 FY24	Q/Q Change
Total Assets	$1.5B	↓ 5.26%
Total Liabilities	$778.2M	↓ 13.72%

	Q3 FY24	Q/Q Change
Total Assets	$1.5B	↑ 3.6%
Total Liabilities	$817.5M	↑ 5.05%

	FY18	Y/Y Change
Operating Cash Flow	$38.2M	↓ 2.6%
Investing Cash Flow	$-42.2M	↑ 8.84%
Financing Cash Flow	$25.0M	↓ 424.02%

	FY19	Y/Y Change
Operating Cash Flow	$41.8M	↑ 9.35%
Investing Cash Flow	$-50.5M	↑ 19.78%
Financing Cash Flow	$-3.8M	↓ 115.13%

	FY20	Y/Y Change
Operating Cash Flow	$57.3M	↑ 37.12%
Investing Cash Flow	$-36.4M	↓ 27.93%
Financing Cash Flow	$-2.2M	↓ 40.63%

	FY21	Y/Y Change
Operating Cash Flow	$98.0M	↑ 71.12%
Investing Cash Flow	$-28.7M	↓ 21.26%
Financing Cash Flow	$-37.0M	↑ 1548.17%

	FY22	Y/Y Change
Operating Cash Flow	$89.2M	↓ 8.99%
Investing Cash Flow	$-32.8M	↑ 14.32%
Financing Cash Flow	$-26.4M	↓ 28.58%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$54.9M	↑ 36.01%
Investing Cash Flow	$-508.6M	↑ 7930.66%
Financing Cash Flow	$428.1M	↓ 3259.96%

Amphastar Pharmaceuticals Inc Technicals Summary

Sell

Neutral

Buy

Amphastar Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Amphastar Pharmaceuticals Inc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Amphastar Pharmaceuticals Inc	-5.4%	4.71%	-23.2%	104.89%	127.68%
Neurocrine Biosciences Inc.	1.97%	-6.15%	7.79%	50.04%	11.14%
Haleon Plc Spon Ads	1.35%	16.11%	18.8%	31.31%	31.31%
Zoetis Inc.	0.3%	-2.27%	-5.33%	-23.89%	44.16%
Viatris Inc.	-2.2%	22.65%	31.13%	3.7%	-21.11%
Catalent, Inc.	3.67%	10.55%	67.08%	-51.26%	19.32%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Amphastar Pharmaceuticals Inc	14.92	14.92	2.77	3.89	0.24	0.09	NA	15.04
Neurocrine Biosciences Inc.	33.98	33.98	0.3	6.54	0.16	0.12	NA	26.87
Haleon Plc Spon Ads	29.36	29.36	1.74	0.34	0.07	0.04	0.02	1.82
Zoetis Inc.	32.98	32.98	2.44	5.88	0.47	0.15	0.01	11.59
Viatris Inc.	224.4	NA	0.08	2.67	-0.04	0.02	0.04	16.58
Catalent, Inc.	211.02	NA	514.17	0.2	-0.11	0.0	NA	19.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Amphastar Pharmaceuticals Inc	Buy	$2.1B	127.68%	14.92	21.8%
Neurocrine Biosciences Inc.	Buy	$12.9B	11.14%	33.98	17.21%
Haleon Plc Spon Ads	Buy	$43.8B	31.31%	29.36	10.75%
Zoetis Inc.	Buy	$79.1B	44.16%	32.98	26.55%
Viatris Inc.	Hold	$15.1B	-21.11%	224.4	-5.87%
Catalent, Inc.	Hold	$11.2B	19.32%	211.02	-9.34%

About Amphastar Pharmaceuticals Inc

amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int

Organization	Amphastar Pharmaceuticals Inc
Employees	1761
CEO	Dr. Ziping Luo Ph.D.
Industry	Health Technology

Management People of Amphastar Pharmaceuticals Inc

Name	Title
Dr. Ziping Luo Ph.D.	Chairman of the Board, Chief Scientist & COO
Dr. Yongfeng Zhang Ph.D.	Co-Founder, President, CEO, Chief Scientific Officer & Director
Mr. William J. Peters M.B.A.	CFO, Executive VP of Finance, Treasurer & Director
Mr. Jacob Liawatidewi M.B.A.	Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director
Mr. Rong Zhou M.S.	Senior EVP of Production & EVP of Scientific Affairs
Mr. Dan Dischner M.B.A.	Senior Vice President of Human Resources & Corporate Communication
Tony Marrs M.B.A., M.P.H., M.S.	Executive VP of Regulatory Affairs & Clinical Operations

Important FAQs about investing in Amphastar Pharmaceuticals Inc from India :

What is Amphastar Pharmaceuticals Inc share price today?

Amphastar Pharmaceuticals Inc (AMPH) share price today is $43.80.

Can Indians buy Amphastar Pharmaceuticals Inc shares?

Yes, Indians can invest in the Amphastar Pharmaceuticals Inc (AMPH) from India.

With INDmoney, you can buy Amphastar Pharmaceuticals Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Amphastar Pharmaceuticals Inc at zero transaction cost.

How can I buy Amphastar Pharmaceuticals Inc shares from India?

It is very easy to buy Amphastar Pharmaceuticals Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Amphastar Pharmaceuticals Inc be purchased?

Yes, you can buy fractional shares of Amphastar Pharmaceuticals Inc with INDmoney app.

What are the documents required to start investing in Amphastar Pharmaceuticals Inc stocks?

To start investing in Amphastar Pharmaceuticals Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.